These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21530928)

  • 1. [Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study].
    Morell L; Carrascosa JM; Ferrándiz C; García-Bustinduy M; Fonseca E; Carretero G; Daudén E; Marrón SE; López-Estebaranz JL; Ferrán M; Sánchez-Regaña M; Muñoz-Santos C; Belinchón I; Puig L;
    Actas Dermosifiliogr; 2011 Jun; 102(5):354-64. PubMed ID: 21530928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical outcomes in patients with psoriasis following discontinuation of efalizumab due to suspension of marketing authorization].
    Baniandrés O; Pulido A; Silvente C; Suárez R; Lázaro P
    Actas Dermosifiliogr; 2010 Jun; 101(5):421-7. PubMed ID: 20525485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension.
    Talamonti M; Teoli M; Botti E; Spallone G; Chimenti S; Costanzo A
    Dermatology; 2011; 222(3):250-5. PubMed ID: 21494026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice.
    Puig L; Roé E; García-Navarro X; Corella F; Alomar A
    Clin Exp Dermatol; 2009 Jun; 34(4):469-75. PubMed ID: 19077105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efalizumab.
    Talamonti M; Spallone G; Di Stefani A; Costanzo A; Chimenti S
    Expert Opin Drug Saf; 2011 Mar; 10(2):239-51. PubMed ID: 21214420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
    Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
    Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective analysis of 72 patients on prior efalizumab subsequent to the time of voluntary market withdrawal in 2009.
    Prater EF; Day A; Patel M; Menter A
    J Drugs Dermatol; 2014 Jun; 13(6):712-8. PubMed ID: 24918562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
    Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
    Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.
    Langley RG; Carey WP; Rafal ES; Tyring SK; Caro I; Wang X; Wetherill G; Gordon KB
    Clin Ther; 2005 Sep; 27(9):1317-28. PubMed ID: 16291408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.
    Costanzo A; Peris K; Talamonti M; Di Cesare A; Fargnoli MC; Botti E; Chimenti S
    Br J Dermatol; 2007 Apr; 156 Suppl 2():17-23. PubMed ID: 17371319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
    Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
    Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis.
    Viguier M; Richette P; Aubin F; Beylot-Barry M; Lahfa M; Bedane C; Delesalle F; Richard-Lallemand MA; Delaporte E; Dubertret L; Bardin T; Bachelez H
    Arthritis Rheum; 2008 Jun; 58(6):1796-802. PubMed ID: 18512820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".
    Nast A; Augustin M; Boehncke WH; Klaus J; Mrowietz U; Ockenfels HM; Philipp S; Reich K; Rosenbach T; Schlaeger M; Sebastian M; Sterry W; Streit V; Weisenseel P; Rzany B
    J Dtsch Dermatol Ges; 2010 Jan; 8(1):65-6. PubMed ID: 20096063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
    Papp KA; Miller B; Gordon KB; Caro I; Kwon P; Compton PG; Leonardi CL;
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S164-70. PubMed ID: 16488338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients.
    Brunasso AM; Puntoni M; Salvini C; Delfino C; Curcic P; Gulia A; Massone C
    Acta Derm Venereol; 2011 Jan; 91(1):44-9. PubMed ID: 21088813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.
    Antoniou C; Stefanaki I; Stratigos A; Avgerinou G; Stavropoulos P; Potouridou I; Polidorou D; Moustou AE; Kosmadaki M; Katsambas AD
    Br J Dermatol; 2007 Apr; 156 Suppl 2():12-6. PubMed ID: 17371318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with high-need psoriasis.
    Antoniou C; Dessinioti C; Vergou T; Stratigos AJ; Avgerinou G; Kostaki M; Katsambas A
    J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1413-20. PubMed ID: 20384690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.
    Papp KA; Toth D; Rosoph L
    BMC Dermatol; 2006 Oct; 6():9. PubMed ID: 17067371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.